# Mauna Kea Technologies and Tasly Pharmaceuticals form joint venture for Cellvizio in China and neurology

Mauna Kea Technologies and Tasly Pharmaceuticals formed a joint venture to develop, manufacture and commercialize Cellvizio in China and globally for neurology and neurosurgery. Mauna Kea will receive $10 million in cash, a 44.1% equity stake, and a 5-year purchase commitment.

- Type: Acquisition
- Announced: 2022-07-11
- Where: China, China
- Value: $10.0M
- Status: completed
- Products: Cellvizio confocal laser endomicroscopy systems
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Mauna Kea Technologies](https://endata.com/companies/64061.md) (partner)
- [Tasly Pharmaceuticals](https://endata.com/companies/64062.md) (partner)

## Sources

- [maunakeatech.com](https://www.maunakeatech.com/news/tasly-pharmaceuticals-and-mauna-kea-technologies-announce-joint-venture-and-licensing-agreements/), 2022-07-11: "We are delighted to partner with Tasly Pharmaceuticals, a life sciences leader in Asia-Pacific with a global presence."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.